36.91
Schlusskurs vom Vortag:
$39.77
Offen:
$40.11
24-Stunden-Volumen:
821.02K
Relative Volume:
0.89
Marktkapitalisierung:
$3.73B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-804.34M
KGV:
-3.9224
EPS:
-9.41
Netto-Cashflow:
$-531.06M
1W Leistung:
-10.91%
1M Leistung:
-5.43%
6M Leistung:
-10.61%
1J Leistung:
-20.74%
Biohaven Ltd Stock (BHVN) Company Profile
Firmenname
Biohaven Ltd
Sektor
Branche
Telefon
203-404-0410
Adresse
215 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie BHVN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
BHVN
Biohaven Ltd
|
36.91 | 3.73B | 0 | -804.34M | -531.06M | -9.41 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
2024-09-16 | Eingeleitet | Jefferies | Buy |
2024-09-04 | Eingeleitet | Bernstein | Outperform |
2024-07-24 | Eingeleitet | Morgan Stanley | Overweight |
2024-02-16 | Eingeleitet | RBC Capital Mkts | Outperform |
2024-02-06 | Eingeleitet | UBS | Buy |
2023-12-22 | Eingeleitet | H.C. Wainwright | Buy |
2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
2023-01-24 | Eingeleitet | SVB Securities | Outperform |
2023-01-04 | Eingeleitet | JP Morgan | Overweight |
2022-12-02 | Eingeleitet | BTIG Research | Buy |
2022-10-26 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2022-10-12 | Eingeleitet | Piper Sandler | Overweight |
2022-08-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
2022-08-08 | Herabstufung | Wedbush | Outperform → Neutral |
2022-05-11 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2021-08-10 | Herabstufung | UBS | Buy → Neutral |
2021-08-03 | Bestätigt | Canaccord Genuity | Buy |
2021-03-11 | Eingeleitet | UBS | Buy |
2020-12-15 | Eingeleitet | H.C. Wainwright | Buy |
2020-04-17 | Eingeleitet | Cowen | Outperform |
2020-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
2020-02-06 | Eingeleitet | Mizuho | Buy |
2019-11-22 | Eingeleitet | Wedbush | Outperform |
2019-06-25 | Bestätigt | Canaccord Genuity | Buy |
2019-05-06 | Eingeleitet | Goldman | Buy |
2019-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2019-03-04 | Bestätigt | Needham | Buy |
2018-07-03 | Bestätigt | Needham | Buy |
2018-07-02 | Bestätigt | Needham | Buy |
2018-04-05 | Herabstufung | Barclays | Overweight → Equal Weight |
2018-02-22 | Bestätigt | Canaccord Genuity | Buy |
2017-12-15 | Eingeleitet | Canaccord Genuity | Buy |
2017-10-03 | Bestätigt | Needham | Buy |
Alle ansehen
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
(BHVN) Technical Pivots with Risk Controls - Stock Traders Daily
Biohaven's troriluzole gains FDA priority review for SCA - MSN
Biohaven (NYSE:BHVN) Now Covered by Deutsche Bank Aktiengesellschaft - MarketBeat
Biohaven stock rises following FDA review and Deutsche Bank's buy rating - MSN
Biohaven (NYSE:BHVN) Shares Gap UpWhat's Next? - MarketBeat
WCM Investment Management LLC Takes Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Mississippi to receive$162.2K of $59.7M Settlement Over Alleged Biohaven Kickbacks - Vicksburg Daily News
Biohaven Ltd. Receives FDA Priority Review for Troriluzole, Boosting Investor Confidence - TipRanks
Why Biohaven Stock Triumphed on Tuesday - The Motley Fool
Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck - Seeking Alpha
Biohaven, Ecolab, Firefly - TradingView
Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues (NYSE:BHVN) - Seeking Alpha
Biohaven stock rises following FDA review and Deutsche Bank’s buy rating - Investing.com Nigeria
Biohaven stock rises following FDA review and Deutsche Bank's buy rating By Investing.com - Investing.com South Africa
Biohaven Says FDA Grants Priority Review to Neurodegenerative Disorder Drug; Shares Rise - Marketscreener.com
Biohaven’s troriluzole NDA in spinocerebellar ataxia accepted by the FDA - TipRanks
Why Biohaven Ltd. Shares Are Tumbling? - TipRanks
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia - PR Newswire
Jennison Associates LLC Makes New $3.64 Million Investment in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
China Universal Asset Management Co. Ltd. Makes New $575,000 Investment in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Kickback Case Settled For $59M - NewsBreak
SG Americas Securities LLC Has $336,000 Holdings in Biohaven Ltd. (NYSE:BHVN) - Defense World
Biohaven Ltd.’s Promising Outlook for Troriluzole in Spinocerebellar Ataxia Amidst FDA Decision - TipRanks
Biohaven FY2025 EPS Forecast Decreased by Leerink Partnrs - MarketBeat
(BHVN) Technical Data - Stock Traders Daily
Leerink Partnrs Decreases Earnings Estimates for Biohaven - Defense World
Nebraska Joins in Settling Kickback Allegations against Biohaven Pharmaceutical Holding Company Ltd. - Rural Radio Network
Nebraska joins in settling kickback allegations against Biohaven - norfolkneradio.com
Pfizer to pay nearly $60M over kickbacks for migraine drug developed by New Haven-based Biohaven - Hartford Business Journal
Multiple System Atrophy (MSA) Market 2025-2032 Business - openPR
Nebraska joins multi-state settlement against Biohaven Pharmaceutical for kickback allegations - NEWS CHANNEL NEBRASKA
Nebraska joins in settling kickback allegations against Biohaven Pharmaceutical Holding Company Ltd. - News Channel Nebraska
Finanzdaten der Biohaven Ltd-Aktie (BHVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):